Indacterol/glycopyrronium/mometasone furoate (Enerzair®) is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting β2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||13/05/2020|
|Rapid review completed||10/06/2020|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that indacterol/glycopyrronium/mometasone furoate (Enerzair®) be considered for reimbursement*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.